To investigate the effect of epigenetic remodeling as a priming agent to potentiate cancer immunotherapeutic approaches, we first evaluated the effect of DAC on MHC class I and PD-L1 expression in low-MHC class I-expressing melanoma and high-MHC class I-expressing TNBCs cell lines.19 This evidence concerns the gene CD274 and cancer.